CX3CR1 and familial dilated cardiomyopathy: This work provides strong evidence that targeting the CX3CR1 signaling pathway represents an attractive approach to attenuate deleterious components of the inflammatory process in the setting of DCM, providing a novel therapeutic target for future studies.